Clinical Trials Logo

Clinical Trial Summary

To Strengthen tuberculosis education and awareness among physicians in Assiut city in the framework of national tuberculosis control program.


Clinical Trial Description

Tuberculosis (TB) remains a major global health problem. According to the World Health Organization (WHO), an estimated global total of 10.6 million people fell ill with TB in 2021, equivalent to 134 cases per 100 000 populations. About 1.5 million people die from TB each year - making it the 13th leading cause of death worldwide . Until the coronavirus (COVID-19) pandemic, TB was the leading cause of death from a single infectious agent, ranking above human immunodeficiency virus (HIV). TB is present in all countries but it is highly prevalent among the low socioeconomic section of the population and marginalized sections of the community . TB is an infectious bacterial disease caused by Mycobacterium tuberculosis (Mtb), which is transmitted between humans through the respiratory route and most commonly affects the lungs, but can damage any tissue . Only about 10 percent of individuals infected with Mtb progress to active TB disease within their lifetime; the remainder of persons infected successfully contain their infection. One of the challenges of TB is that the pathogen persists in many infected individuals in a latent state for many years and can be reactivated to cause disease. According to WHO, approximately one-quarter of the world's population is latently infected with Mtb . The risk of progression to TB disease after infection is highest soon after the initial infection and increases dramatically for persons co-infected with HIV or other immune-compromising conditions . TB is a curable and preventable disease. TB drugs are administered in different combinations of four first-line drugs which form the core of treatment regimens in the initial treatment phase of 6-9 months. Several reasons account for the failure of TB therapy such as (i) late diagnosis, (ii) lack of timely and proper administration of effective drugs, (iii) long treatment duration, (iv) non adherence to drug regimen and (v) evolution of drug-resistant TB strains. Drug-resistant TB(DR-TB) poses a significant challenge to TB therapy and control programs . In 2014 and 2015, all Member States of WHO and the United Nations (UN) committed to ending the TB epidemic, through their adoption of WHO's End TB Strategy and the UN Sustainable Development Goals (SDGs). The UN SDGs include ending the TB epidemic by 2030 under Goal 3. WHO's End TB Strategy aims to reduce TB deaths by 90% and cut new cases by 80% between 2015 and 2030, and ensure that no family is burdened with catastrophic health expenditure due to TB. In Egypt TB is still a health problem, which affects the young active age group with pulmonary TB more in Lower Egypt, whereas extrapulmonary cases were more in Upper Egypt, especially in the rural community . Egypt is ranked among the mid-level incidence countries and according to a WHO estimation of the TB burden in 2019, the incidence of TB was 12 per 100 000 inhabitants . The Ministry of Health and Population (MOHP) has established the National Tuberculosis Control Program(NTP) in 1979 . The COVID-19 pandemic has undone decades of progress in the fight against TB. Globally, the estimated number of deaths from TB increased between 2019 and 2021, reversing years of decline between 2005 and 2019. The burden of DR-TB is also estimated to have increased between 2020 and 2021, with 450 000 new cases of rifampicin-resistant TB . The most obvious and immediate impact was a large global drop in the reported number of people newly diagnosed with TB. Reductions in the reported number of people diagnosed with TB in 2020 and 2021 suggest that the number of people with undiagnosed and untreated TB has grown, resulting in an increased number of TB deaths and more community transmission of infection and increased numbers of people developing TB . Healthcare workers (HCWs) play a fundamental role in the global fight against TB . Adequate basic knowledge about TB enables the physician to suspect and deal with a TB case, whereas insufficient knowledge will lead to either escaping suspicion or improper dealing with a TB case. The delayed proper diagnosis and management of TB will cause spreading of TB and facilitate the development of resistance to anti-TB drugs . Worldwide, many studies found that HCWs have important knowledge gaps in relation to TB diagnosis, treatment and infection prevention and control; have some negative attitudes and stigma connected with the disease; and engage in poor practices, all of which contribute to their increased risk of infection and negative impacts on patients and the community . In Egypt, previous studies illustrated lower basic knowledge of the studied primary health care (PHC) physicians about TB. In Gharbia Governorate , the mean of satisfactory basic knowledge was 49.6%. Similar results were detected in Menofya Governorate and in Qalyubia Governorate, where the means of satisfactory basic knowledge of the studied physicians about TB were 54.5% and 48.2% respectively. Other study in Behaira Governorate reported a mean of 63% for physicians' knowledge. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05805878
Study type Observational
Source Assiut University
Contact Esraa Mariae
Phone 01025328500
Email Esraaabdelkareem41@aun.edu.eg
Status Not yet recruiting
Phase
Start date October 2023
Completion date October 2026

See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2